Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars A Driving Force Behind Korean Pharma Exports

This article was originally published in PharmAsia News

Executive Summary

Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.

Advertisement

Related Content

Remsima Stars In Orion Pharma’s First Half

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel